ECM Weekly (3 Aug 2019) - Sterling&Wilson, Spandana Sphoorty, Smoore, AllHome, JS Global
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
612 Views
Alphamab IPO: Interims from Merck's Breast Cancer Trial Bodes Well for Alphamab and Junshi
Last night, Merck & Co Inc. (MRK US) announced that its Keytruda hits primary endpoint in Phase III (KEYNOTE-522) clinical trial in the...
576 Views
This Week in Blockchain & Cryptos: Visa, Ubisoft, GM, Target, FB & Apple Reveal Blockchain Plans
Bitcoin saw a correction during the first week of June but has recovered quickly. Bitcoin's leading indicators remain positive, giving a bullish...
607 Views
Immuno-Oncology Drugs in Adjuvant Lung: The Next Frontier in Strengthening Moats
The potential for Merck and Roche looks underappreciated.Innovation in immuno-oncology drugs has supported the moats for Merck & Co Inc. (MRK...
562 Views
Versum Materials – Merck KGaA Not Going Away (Part II)
Since my initial report on Versum Materials (VSM US) last week, Versum Materials – Entegris Beaten to the Punch by Merck KGaA , I’ve dug deeper...
363 Views